Hikma outlines growth strategy, healthcare stock in sector comparison

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-28, 14:31.

Hikma Pharmaceuticals PLC (GB00B128J450) remains positioned as a mid-cap generics and branded pharmaceuticals player in the UK-listed healthcare universe. Investors continue to assess its long-term strategy against larger peers such as GSK and AstraZeneca on the London Stock Exchange.

How Hikma plans to grow

Hikma Pharmaceuticals describes a three-pillar strategy built around injectables, branded generics and contract manufacturing, with emphasis on emerging markets in the Middle East and North Africa. The company highlights capacity investments in sterile injectables facilities and a pipeline of oncology and anti-infective products in recent investor materials.Hikma investor presentation on strategy Hikma also flags its role as a supplier of critical hospital medicines to the US market, including anaesthetics and critical care products, which supports recurring revenue in its injectables segment.

Position in the healthcare peer group

On the London market, Hikma Pharmaceuticals trades alongside larger diversified peers such as GSK and AstraZeneca, which focus more heavily on patented medicines and vaccines. By contrast, Hikma’s mix of generic injectables and branded products places it closer to companies like Teva in terms of business model, though with a regional strength in the Middle East and North Africa. Analysts covering the UK healthcare sector often reference Hikma as a specialised generics and injectables provider when comparing margin profiles and capital allocation.Reuters UK healthcare sector overview

The products behind Hikma

Hikma’s portfolio includes hospital injectables such as propofol for anaesthesia and a range of anti-infective and oncology treatments supplied to US and European healthcare systems. The company also markets branded generics in markets such as Jordan and Saudi Arabia, where it sells cardiovascular and central nervous system medicines under local brand names. In addition, Hikma engages in contract manufacturing for other pharmaceutical companies, leveraging its sterile production facilities.

Where the Hikma stock trades

The Hikma Pharmaceuticals shares (GB00B128J450) trade on the London Stock Exchange in pounds sterling, with pricing reflecting its position in the UK-listed healthcare sector. The stock is treated by many investors as a specialised generics and injectables exposure alongside larger pharma peers.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. All data are based on sources believed to be reliable but cannot be guaranteed.